Quent Capital LLC Increases Stake in Boston Scientific Corporation $BSX

Quent Capital LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,455 shares of the medical equipment provider’s stock after buying an additional 231 shares during the quarter. Quent Capital LLC’s holdings in Boston Scientific were worth $371,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at about $27,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific in the second quarter valued at about $37,000. Finally, Activest Wealth Management lifted its stake in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BSX. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Truist Financial raised their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research note on Wednesday. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $120.79.

Insider Activity

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $97.30 on Friday. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The stock has a market capitalization of $144.17 billion, a P/E ratio of 57.91, a P/E/G ratio of 2.34 and a beta of 0.61. The firm’s 50-day moving average is $102.93 and its two-hundred day moving average is $102.06. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.